Starvation for glutamine results in a phenotype similar the vacuolar membrane. Moreover, large-scale geto TOR inactivation, inasmuch as it causes nuclear lonetic analyses of the EGO complex confirm the exiscalization and activation of Gln3 and of the heterotence of a growth control mechanism originating at dimeric transcription factor Rtg1/Rtg3, which in turn the vacuolar membrane and pinpoint the amino acid activates genes whose products (e.g., mitochondrial glutamine as a key metabolite in TOR signaling. 
translation initiation factor 2 (eIF2α), thereby slowing the rate of GDP-GTP exchange on eIF2. This process reduces the overall translation initiation rate, yet specifically favors translation of the GCN4 mRNA, which encodes a transactivator of amino acid biosynthetic genes (Hinnebusch, 1997) . Under conditions of TOR depletion, translation of such critical factors as Gcn4 is accomplished by regeneration of internal nutrient pools via macroautophagic recycling of cytoplasmic material (Jacinto and Hall, 2003; Levine and Klionsky, 2004) .
The pathways that regulate entry of cells into a quiescent growth phase as a result of downregulation of TOR and/or nutrient starvation are understood in considerable detail, yet the mechanisms that control the transition from quiescence back to proliferation have received surprisingly little attention thus far (Gray et al., 2004). Here, we describe the discovery of a vacuolar membrane associated protein complex, which plays an essential function in exit from rapamycin-induced growth arrest: the EGO complex. We demonstrate that the EGO complex, in conjunction with TOR, positively regulates microautophagy. This process, which counterbalances the massive rapamycin-induced, macroautophagy-mediated membrane influx toward the vacuo- three of these were defective in phospholipid and ADH1-GST; lane 4). Cell lysates (Input) and GST pull-down fractions amino acid metabolism (i.e., pib2D, sac3D, and hom2D), were subjected to PAGE and immunoblots were probed using antione in molecular chaperone activity (ydj1D), and one in myc, anti-GFP, or anti-GST antibodies as indicated.
an as-yet-unidentified cellular process (ydl172cD). The remaining three mutants (ykr007wD/meh1D/ego1D, gtr2D, and ybr077cD/ego3D) were grouped in a sepanot shown). These results, together with our observarate class based on our findings that the corresponding tion that rapamycin-induced inhibition of protein syngene products act in a common protein complex as thesis (as assayed by both incorporation of radioacassayed by both two-hybrid ( Figure 1A ) and coprecipitively labeled amino acids into TCA precipitable tation analyses ( Figure 1B) . Notably, the ykr007wD/ material [ Figure 2E ; and data not shown] and phosmeh1D/ego1D, gtr2D, and ybr077cD/ego3D mutants phorylation of eIF2α on Ser 51 [ Figure 2F ]) could be normally responded to rapamycin treatment by tranreversed in wild-type cells, but not in the ykr007wD/ scriptional induction of a characteristic set of stress remeh1D/ego1D, gtr2D, and ybr077cD/ego3D mutants, sponse genes (e.g., HSP12, HSP26, and GRE1; Figure argue strongly that the corresponding three proteins 2A), transcriptional repression of SSB1 (Figure 2A ), acare essential for resumption of growth following rapacumulation of glycogen ( Figure 2B ), induction of macromycin treatment. For the remainder of the text, we will autophagy ( Figures 2C and 2D) , and inhibition of prorefer to Ykr007W/Meh1/Ego1 as Ego1, Ybr077C/Ego3 tein synthesis (Figures 2E and 2F) . Thus, by several as Ego3, and the protein complex containing Ego1, criteria, the three mutants normally enter into the rapaGtr2, and Ego3 as the EGO complex. mycin-induced growth arrest program. Importantly, despite their defect in recovery from rapamycin treatment ( Figure 2G ), the ykr007wD/meh1D/ego1D, gtr2D, and
The EGO Complex Harbors a Member of the RagA Subfamily of Ras-Related GTPases ybr077cD/ego3D mutants did not significantly lose viability (as assayed by trypan blue exclusion experiGtr2 has previously been described as a member of a new G protein family that includes its yeast homolog ments) during the rapamycin treatment and during at least the first 48 hr following rapamycin release (data Gtr1 and the mammalian RagA, -B, -C, and -D (Naka- Figure 3A) and caused a defect in recovery from rapamycin treatment and rapamycin hypersensitivity when expressed in wild-type cells (Figures 3A and  3B ). This dominant negative phenotype could result from the failure of the presumably GTP-locked Gtr2
Q66L
protein to effectively release a critical downstream effector and indicates that Gtr2 may function as a small GTPase that becomes essential for growth under conditions of diminished TORC1 activity. In support of this notion, we found that loss of Gtr2, like loss of Ego1 and Ego3, resulted in pronounced rapamycin hypersensitivity ( Figures 2G and 3C) . Moreover, since overproduction of either Gtr2, or Ego3 conferred significantly enhanced resistance to rapamycin treatment ( Figure 3D ), our data indicate that the EGO complex functions in the rapamycin-sensitive TORC1 network. Figure  4C) . A large part of Gtr2-GFP, however, was lost from this fraction and solubilized readily into the supernatant, indicating that Gtr2 is more weakly associated to the vacuolar membrane than Ego1 and Ego3. (Notably, the levels of Ego1-GFP, Gtr2-GFP, and Ego3-GFP did not dramatically change during the first 3 hr of rapamycin treatment; Figure 4D ).
EGO and Rapamycin-Sensitive TOR Complexes Regulate Microautophagy
The vacuoles of EGO mutants, like the ones in wildtype cells, appeared normal during exponential growth and steadily increased in size in response to rapamycin treatment ( Figure 5A ). This phenotype results from the during the recovery phase from rapamycin treatment in to form microautophagic vesicles even in the presence of 50 ng/ml rapamycin ( Figure 5E ), indicating that the corresponding ego1D and ego3D mutants, respectively; Figure 5C ). These vesicles, which could be released in EGO complex acts downstream and/or in parallel of TORC1 to control microautophagy. less than 90 s ( Figure 5D ), moved freely around the vacuolar lumen indicating that they had fully separated We also tested whether the phenotype of an EGO complex mutant may be due to a failure of membrane from the vacuolar membrane. Since the formation of these vesicles, which was also observed in wild-type recycling via the retrograde traffic out of the vacuole. To this end, we determined in both wild-type and gtr2D cells recovering from rapamycin treatment (Figure 5B ), meets the classical definition of microautophagy, we cells the localization of an ALP variant (RS-ALP) with an engineered Golgi-retrieval sequence (FXFXD) at its conclude that the EGO complex is required for the induction of microautophagy during recovery from rapa-N-terminal region (Bryant et al., 1998) . RS-ALP exhibited only the punctate staining pattern that is charactermycin treatment. We could not observe (neither in wildtype nor in ego mutant cells) microautophagic vesicle istic of localization to the trans-Golgi network irrespective of either rapamycin treatment or the presence or formation during the treatment with rapamycin, and therefore further conclude that TORC1 positively conabsence of Gtr2 ( Figure 6A ). In addition, Golgi membrane-containing cell fractions of exponentially growtrols microautophagy. This conclusion is supported by the recent finding that rapamycin specifically inhibits ing wild-type and gtr2D cells and of corresponding rapamycin treated cells (6 hr) contained both pro-RS-ALP, microautophagic scission of vesicles into the vacuolar lumen as assayed in a cell-free microautophagy assay as well as the proteolytically matured mRS-ALP (data not shown). Thus, the ratio between RS-ALP influx to (Kunz et al., 2004) . Finally, wild-type cells overproducing Gtr2 or Ego3, but not control cells, were competent and retrieval from the vacuolar membrane does not sig- Original YKO mutants were backcrossed with ego1D (CDV207), gtr2D (CDV209), or ego3D (CDV208) mutants. Spores carrying both mutations were selected and assayed for recovery from rapamycin treatment as in Figure 2G except that recovery was additionally tested on YPD plates containing 2 ng/ml rapamycin. To verify that the suppressive effect is due to the loss of function mutation, selected double mutants were complemented with a plasmid harboring the corresponding wild-type gene and assayed (following growth on SD) for recovery from rapamycin treatment as in Figure 2G . Notably, the observed effect of glutamate was strongly induced growth arrest of all three EGO mutants ( Figures  7C and 7D ). These mutations include (1) cbp6D, mrf1D, dependent on TORC1 function, since it was entirely abolished in the presence of very low, subinhibitory mrpl23D, and rmd9D, all of which exhibit severe mitochondrial defects and hence are expected to induce levels of rapamycin (i.e., 2 ng/ml; Figure 7B npr1D, which causes defects in degradation of amino acid permeases (Schmidt et al., 1998) , and which has that suppressed the defect in exit from rapamycin-recently been reported to slightly increase glutamine fically required to counterbalance the massive membrane influx toward the vacuolar membrane resulting levels (Crespo et al., 2004 ) (an effect that may be more from rapamycin-induced macroautophagy. The obserpronounced following rapamycin treatment). Imporvation that EGO complex function becomes essential tantly, the suppressive effects of the isolated mutations for growth when TORC1 activity is reduced (i.e., in the depended on a fully functional TORC1 complex, as ilpresence of subinhibitory rapamycin levels or in the ablustrated by the fact that the presence of very low, subsence of Tor1) substantiates this notion. An interesting inhibitory levels of rapamycin (i.e., 2 ng/ml) during the consequence of this genetic interaction is that mutarecovery phase (a concentration that does not prevent tions, which positively or negatively modulate TORC1 the recovery from rapamycin treatment of wild-type activity, are expected to either alleviate or aggravate, cells; data not shown) completely abolished the obrespectively, the defects exhibited by EGO complex served suppressive effects ( Figure 7C ). Taken together, mutants. To identify potential regulators of TORC1, we our large-scale genetic analyses converge on glutatherefore performed a genome-wide screen for mutamine as a key molecule that may act in the TOR signaltions that either suppressed the gtr2D phenotype, or, ing pathway upstream of TORC1 ( Figure 7D) .
conversely, resulted in a synthetic lethal/sick phenotype when combined with gtr2D. As schematically ilDiscussion lustrated in Figure 7D , these studies identified a regulatory network of proteins that converges on the amino In a first attempt to unravel the mechanisms that conacid glutamine as a key metabolite in TOR signaling. trol exit from quiescence, we sought to identify those These finding are in line with those of a previous report yeast mutants that are specifically defective in exit from (Crespo et al., 2002) . Nevertheless, we would like to rapamycin-induced growth arrest. Here, we focused emphasize that our genetic data allow at present no our efforts on the characterization of three mutants, definite exclusion of alternative models in which the namely ego1D, gtr2D, and ego3D, and showed that various suppressor mutations may impinge on TORC1 they are likely defective in the same (EGO) protein comvia a glutamine-independent mechanism(s). plex. Several observations support this conclusion.
An important finding of our present study is that diFirst, all three mutants exhibit the same defects in both verse readouts, which are negatively controlled by resumption of growth following rapamycin treatment TORC1 (e.g., glycogen accumulation, phosphorylation and growth in the presence of subinhibitory rapamycin of eIF2α on Ser 51, and macroautophagy; Figures 2B levels. Second, these defects can be reversed in all and 2F; and data not shown), depended on the presthree mutants by the same suppressor mutations (inence of Ego1, Gtr2, and Ego3 during recovery from racluding npr1D, arg3D, cpa2D, and cbp6D). sick with either loss of EGO complex function or reEgo1 is associated with the vacuolar membrane duced TOR activity. Interestingly, in this context, our through its covalently attached N-terminal myristoyl SGA analysis recovered the tif3D mutant, which meets group (and its interaction with Ego3); and (3) Ego3 is both of these requirements, i.e., it is hypersensitive to anchored in the vacuolar membrane via its presumed rapamycin (Parsons et al., 2004 ) and synthetically sick membrane-spanning and lipid binding domains (and its in combination with gtr2D ( Figure 7A) . Tif3, the yeast interaction with Ego1; Figure 7D ). In support of this toeIF4B homolog, is thought to stimulate eIF4A helicase pology model, we observed that loss of individual comactivity to enhance unwinding of inhibitory secondary ponents of the EGO complex did not significantly affect structures in the 5# untranslated region of mRNAs. In the localization of the other two, except for loss of Ego1 mammalian cells, eIF4B has been identified as an indithat resulted in a partial redistribution of Gtr2-GFP to rect target of mTOR and suggested to be particularly the cytoplasm (data not shown).
important FD25, respectively, which express the corresponding GST-tagged YKR007W/EGO1-myc13-kanMX6 and GTR2-myc13-kanMX6 transproteins from integrative plasmids. Bound proteins were eluted formed into KT1961 to create FD19 and FD21, respectively) were with sample buffer (5 min, 95°C) and subjected to standard immudone as described (Longtine et al., 1998) . Diploid strains FD24 noblot analysis for detection of coprecipitated proteins. (ego1::natMX4/EGO1 GTR2-myc13-kanMX6/GTR2 EGO3-GFP-TRP1/EGO3) and FD25 (EGO1-myc13-kanMX6/EGO1 GTR2-GFP-TRP1/GTR2 ego3::natMX4/EGO3) were constructed by a series of Synthetic Genetic Array Analysis combinatorial mating and sporulation among the isogenic strains Synthetic genetic array (SGA) analysis was performed as described CDV210, CDV214, and FD21, and CDV211, CDV215, and FD19, re-(Tong et al., 2001), using a gtr2D mutant (CDV209) as the bait strain. spectively. CDV266-1D (pho8D::kanMX) and CDV266-22A (gtr2D::
In total, four double-deletion combinations were found that renatMX4 pho8D::kanMX) are segregants of CDV266, which was cresulted in a synthetic growth defect and fulfilled the following two ated by mating CDV209 and the YKO strain pho8::DkanMX4 (Gicriteria: (1) the corresponding YKO single mutant strains (i.e., tor1D, aever et al., 2002). Strains were grown at 30°C in standard rich tif3D, rtg2D, and rtg3D) also exhibited a synthetic growth defect medium (YPD) with 2% glucose or synthetic defined medium (SD) when combined with the dominant negative Gtr2 Q66L (expressed complemented with the appropriate nutrients for plasmid maintefrom pCDV992), and (2) the double-deletion combinations could be nance and either 2% glucose or 2% galactose and 1% raffinose complemented as indicated in Figures 7A and 7B . The double mu-(SGal/Raf) as carbon source (Guthrie and Fink, 1991). Standard getant collection was also screened for suppressors of the gtr2D-netic manipulations were used (Guthrie and Fink, 1991). Gene deledependent defect in exit from rapamycin-induced growth arrest. tions were confirmed by phenotypic analyses and/or PCR with
In total, 8 suppressors could be confirmed by the ability of the corresponding YKO single mutants (i.e., fpr1D, cbp6D, mrf1D, gene-specific primers. 
